HeliTrax FAQ Contact Us Forward to a Friend

Hemophilia Resources

HeliTrax^SM

Introducing the new HeliTrax^SM System—Bringing you and your patients closer together

Electronic patient diary makes data entry easier for you and your patients
Patients can transmit data from anywhere with a true wireless, Internet-based device
Web site provides a clear, clinical snapshot of your patient—available in one report at any time
Unique camera feature and high-priority alerts for rapid assessment of emergency bleeding events

Learn More

Reimbursement

CSL Behring provides a range of reimbursement services, including individual claims processing reviews, assistance in appeals, insurance investigations into product coverage, and prior approvals for therapies authorization. To speak with a representative, call the Reimbursement Answerline at 1-800-676-4266 Monday through Friday from 8 a.m. to 5 p.m. ET. Or, visit our online Reimbursement Resource Center.

BILLING CODES

HCPCS CODE	ICD-9-CM	CPT CODES
J-7192- FACTOR VIII (ANTIHEMOPHILIC FACTOR RECOMBINANT), PER IU	286.0 - CONGENITAL FACTOR VIII DISORDER	96374 96376 96365

This resource provides information from a complex and evolving medical coding system. The treating physician is solely responsible for diagnosis coding and determination of the appropriate ICD-9-CM codes that describe the patient’s condition and are supported by the medical record. All codes listed in this guide are for informational purposes and are not an exhaustive list. The CPT, HCPS, and ICD-9-CM codes provided are based on AMA or CMS guidelines. The billing party is solely responsible for coding of services (eg, CPT coding). Because government and other third-party payor coding requirements change periodically, please verify current coding requirements directly with the payor being billed.

NDC CODES

CODE	DESCRIPTION
NDC 0053-8131-02	Approximately 250 IU per bottle
NDC 0053-8132-02	Approximately 500 IU per bottle
NDC 0053-8133-02	Approximately 1000 IU per bottle
NDC 0053-8134-02	Approximately 2000 IU per bottle
NDC 0053-8135-02	Approximately 3000 IU per bottle

FactorPlus^SM - The Helixate^® FS Free Trial Program

We are pleased to provide the hemophilia community with the option of trying Helixate^® FS at no charge. To obtain a free trial of Helixate^® FS for one of your patients, simply complete the Helixate^® FS Product Request form and fax it to the number shown on the form.

Find a representative

Find a Helixate^® FS representative near you. More>>

For technical and medical questions about Helixate^® FS, please call the CSL Behring Medical Affairs Department at 1-800-504-5434.

Important Safety Information

Helixate^® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate^® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate^® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.